Determination of editors at the novel A-to-I editing positions - PubMed (original) (raw)
Determination of editors at the novel A-to-I editing positions
Yoshinori Nishimoto et al. Neurosci Res. 2008 Jun.
Abstract
A-to-I RNA editing modifies a variety of biologically important mRNAs, and is specifically catalyzed by either adenosine deaminase acting on RNA type 1 (ADAR1) or type 2 (ADAR2) in mammals including human. Recently several novel A-to-I editing sites were identified in mRNAs abundantly expressed in mammalian organs by means of computational genomic analysis, but which enzyme catalyzes these editing sites has not been determined. Using RNA interference (RNAi) knockdowns, we found that cytoplasmic fragile X mental retardation protein interacting protein 2 (CYFIP2) mRNA had an ADAR2-mediated editing position and bladder cancer associated protein (BLCAP) mRNA had an ADAR1-mediated editing position. In addition, we found that ADAR2 forms a complex with mRNAs with ADAR2-mediated editing positions including GluR2, kv1.1 and CYFIP2 mRNAs, particularly when the editing sites were edited in human cerebellum by means of immunoprecipitation (IP) method. CYFIP2 mRNA was ubiquitously expressed in human tissues with variable extents of K/E site editing. Because ADAR2 underactivity may be a causative molecular change of death of motor neurons in sporadic amyotrophic lateral sclerosis (ALS), this newly identified ADAR2-mediated editing position may become a useful tool for ALS research.
Similar articles
- Newly identified ADAR-mediated A-to-I editing positions as a tool for ALS research.
Kwak S, Nishimoto Y, Yamashita T. Kwak S, et al. RNA Biol. 2008 Oct-Dec;5(4):193-7. doi: 10.4161/rna.6925. Epub 2008 Oct 5. RNA Biol. 2008. PMID: 18971634 - Novel etiological and therapeutic strategies for neurodiseases: RNA editing enzyme abnormality in sporadic amyotrophic lateral sclerosis.
Hideyama T, Yamashita T, Nishimoto Y, Suzuki T, Kwak S. Hideyama T, et al. J Pharmacol Sci. 2010;113(1):9-13. doi: 10.1254/jphs.09r21fm. Epub 2010 Apr 16. J Pharmacol Sci. 2010. PMID: 20424386 Review. - Effects of antidepressants on GluR2 Q/R site-RNA editing in modified HeLa cell line.
Sawada J, Yamashita T, Aizawa H, Aburakawa Y, Hasebe N, Kwak S. Sawada J, et al. Neurosci Res. 2009 Jul;64(3):251-8. doi: 10.1016/j.neures.2009.03.009. Epub 2009 Mar 25. Neurosci Res. 2009. PMID: 19447293 - Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons.
Hideyama T, Yamashita T, Aizawa H, Tsuji S, Kakita A, Takahashi H, Kwak S. Hideyama T, et al. Neurobiol Dis. 2012 Mar;45(3):1121-8. doi: 10.1016/j.nbd.2011.12.033. Epub 2011 Dec 28. Neurobiol Dis. 2012. PMID: 22226999 - AMPA receptor-mediated neuronal death in sporadic ALS.
Kwak S, Hideyama T, Yamashita T, Aizawa H. Kwak S, et al. Neuropathology. 2010 Apr;30(2):182-8. doi: 10.1111/j.1440-1789.2009.01090.x. Epub 2010 Jan 19. Neuropathology. 2010. PMID: 20102521 Review.
Cited by
- Revealing Differential RNA Editing Specificity of Human ADAR1 and ADAR2 in Schizosaccharomyces pombe.
Zhang N, Chen P, Cui Z, Zhou X, Hao C, Xie B, Hao P, Ye BC, Li X, Jing X. Zhang N, et al. Genes (Basel). 2024 Jul 9;15(7):898. doi: 10.3390/genes15070898. Genes (Basel). 2024. PMID: 39062677 Free PMC article. - Spatiotemporal and genetic regulation of A-to-I editing throughout human brain development.
Cuddleston WH, Fan X, Sloofman L, Liang L, Mossotto E, Moore K, Zipkowitz S, Wang M, Zhang B, Wang J, Sestan N, Devlin B, Roeder K, Sanders SJ, Buxbaum JD, Breen MS. Cuddleston WH, et al. Cell Rep. 2022 Nov 1;41(5):111585. doi: 10.1016/j.celrep.2022.111585. Cell Rep. 2022. PMID: 36323256 Free PMC article. - Cytoplasmic FMR1 interacting protein (CYFIP) family members and their function in neural development and disorders.
Biembengut ÍV, Silva ILZ, Souza TACB, Shigunov P. Biembengut ÍV, et al. Mol Biol Rep. 2021 Aug;48(8):6131-6143. doi: 10.1007/s11033-021-06585-6. Epub 2021 Jul 29. Mol Biol Rep. 2021. PMID: 34327661 Review. - RNA editing at a limited number of sites is sufficient to prevent MDA5 activation in the mouse brain.
Kim JI, Nakahama T, Yamasaki R, Costa Cruz PH, Vongpipatana T, Inoue M, Kanou N, Xing Y, Todo H, Shibuya T, Kato Y, Kawahara Y. Kim JI, et al. PLoS Genet. 2021 May 13;17(5):e1009516. doi: 10.1371/journal.pgen.1009516. eCollection 2021 May. PLoS Genet. 2021. PMID: 33983932 Free PMC article. - Dysregulations of Functional RNA Modifications in Cancer, Cancer Stemness and Cancer Therapeutics.
Uddin MB, Wang Z, Yang C. Uddin MB, et al. Theranostics. 2020 Feb 10;10(7):3164-3189. doi: 10.7150/thno.41687. eCollection 2020. Theranostics. 2020. PMID: 32194861 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous